Rigel Pharmaceuticals (RIGL) Total Liabilities (2010 - 2026)
Rigel Pharmaceuticals (RIGL) posted quarterly Total Liabilities of $104.7 million for Q1 2026, down 33.48% year-over-year from $157.4 million in Q1 2025, and down 14.25% quarter-over-quarter from $122.1 million in Q4 2025.
Rigel Pharmaceuticals (RIGL) Total Liabilities (2010 - 2026) Analysis & Trends
Rigel Pharmaceuticals' Total Liabilities history runs 17 years deep, the most recent figure standing at $104.7 million for Q1 2026.
- In Q1 2026, Total Liabilities fell 33.48% year-over-year to $104.7 million; the TTM figure through Mar 2026 stood at $104.7 million (down 33.48% YoY), while the FY2025 annual figure was $122.1 million, down 24.01% from the prior year.
- Total Liabilities for Q1 2026 stood at $104.7 million, down from $122.1 million in the prior quarter.
- The five-year high for Total Liabilities was $160.7 million in Q4 2024, with the low at $104.7 million in Q1 2026.
- The 5-year median for Total Liabilities is $147.2 million (2023), against an average of $140.7 million.
- The sharpest annual moves came in 2022 and 2023: Total Liabilities plunged 38.02% in 2022, then gained 27.29% in 2023.
- Rigel Pharmaceuticals' Total Liabilities stood at $147.9 million in 2022, then retreated by 1.37% to $145.9 million in 2023, then grew by 10.16% to $160.7 million in 2024, then retreated by 24.01% to $122.1 million in 2025, then retreated by 14.25% to $104.7 million in 2026.
- Business Quant data shows RIGL's Total Liabilities at $104.7 million in Q1 2026, $122.1 million in Q4 2025, and $124.9 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 7.18 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 10.02 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.62 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 1.72 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 4.00 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 7.02 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 10.03 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 4.20 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 1.35 Bn |
| 10 | Rigel Pharmaceuticals | 795.39 Mn | 700.06 Mn | 70.18 Mn | 95.64 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 95.64 Mn |
| Mar 31, 2026 | 104.71 Mn |
| Dec 31, 2025 | 122.11 Mn |
| Sep 30, 2025 | 124.93 Mn |
| Jun 30, 2025 | 124.80 Mn |
| Mar 31, 2025 | 157.41 Mn |
| Dec 31, 2024 | 160.69 Mn |
| Sep 30, 2024 | 154.06 Mn |
| Jun 30, 2024 | 158.32 Mn |
| Mar 31, 2024 | 158.19 Mn |
| Dec 31, 2023 | 145.87 Mn |
| Sep 30, 2023 | 147.16 Mn |
| Jun 30, 2023 | 145.21 Mn |
| Mar 31, 2023 | 147.87 Mn |
| Dec 31, 2022 | 147.90 Mn |
| Sep 30, 2022 | 115.61 Mn |
| Jun 30, 2022 | 128.00 Mn |
| Mar 31, 2022 | 149.07 Mn |
| Dec 31, 2021 | 136.95 Mn |
| Sep 30, 2021 | 186.52 Mn |